CA-125 levels in predicting optimal cytoreductive surgery in patients with advanced epithelial ovarian carcinoma

被引：11
|
作者：
Alcázar, JL [1 ]
Miranda, D [1 ]
Unanue, A [1 ]
Novoa, E [1 ]
Alemán, S [1 ]
Madariaga, L [1 ]
机构：
[1] Univ Navarra, Sch Med, Univ Navarra Clin, Dept Obstet & Gynecol, E-31080 Pamplona, Spain
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS | 2004年 / 84卷 / 02期
关键词：
CA-125; optimal cytoreduction; advanced ovarian cancer;
D O I：
10.1016/j.ijgo.2003.10.006
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
[No abstract available]
引用
收藏
页码：173 / 174
页数：2
相关论文
共 50 条
  • [31] Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer
    Kang, Sokbom
    Kim, Tae-Joong
    Seo, Sang-Soo
    Kim, Byoung-Gie
    Bae, Duk-Soo
    Park, Sang-Yoon
    GYNECOLOGIC ONCOLOGY, 2011, 120 (01) : 18 - 22
  • [32] The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study
    Bai, Huimin
    Sha, Guisha
    Xiao, Meizhu
    Gao, Huiqiao
    Cao, Dongyan
    Yang, Jiaxin
    Chen, Jie
    Wang, Yue
    Zhang, Zhenyu
    Shen, Keng
    ONCOTARGET, 2016, 7 (13) : 15566 - 15576
  • [33] Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy
    Rodriguez, Noah
    Rauh-Hain, J. Alejandro
    Shoni, Melina
    Berkowitz, Ross S.
    Muto, Michael G.
    Feltmate, Colleen
    Schorge, John O.
    del Carmen, Marcela G.
    Matulonis, Ursula A.
    Horowitz, Neil S.
    GYNECOLOGIC ONCOLOGY, 2012, 125 (02) : 362 - 366
  • [34] IMMUNOSUPPRESSIVE ACIDIC PROTEIN AND CA-125 LEVELS IN PATIENTS WITH OVARIAN-CANCER
    CASTELLI, M
    BATTAGLIA, F
    SCAMBIA, G
    PANICI, PB
    FERRANDINA, G
    MILEO, AM
    MANCUSO, S
    FERRINI, U
    ONCOLOGY, 1991, 48 (01) : 13 - 17
  • [35] The relationship between ovarian volume and serum CA-125 levels
    Gulec, U. K.
    Paydas, S.
    Guzel, A. B.
    Vardar, M. A.
    Urunsak, I. F.
    Cetin, M. T.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2014, 35 (03) : 280 - 283
  • [36] What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
    Chi, D. S.
    Eisenhauer, E. L.
    Lang, J.
    Huh, J.
    Haddad, L.
    Abu-Rustum, N. R.
    Sonoda, Y.
    Levine, D. A.
    Hensley, M.
    Barakat, R. R.
    GYNECOLOGIC ONCOLOGY, 2006, 103 (02) : 559 - 564
  • [37] Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer
    Ducoulombier, Simon
    Golfier, Francois
    Colomban, Olivier
    Benayoun, David
    Bolze, Pierre-Adrien
    Tod, Michel
    You, Benoit
    ANTICANCER RESEARCH, 2017, 37 (12) : 6879 - 6886
  • [38] TUMOR-MARKER CA-125 LEVELS IN STAGE-I EPITHELIAL OVARIAN-CANCER
    NAGELE, F
    VAVRA, N
    KURZ, C
    SEVELDA, P
    WIENER KLINISCHE WOCHENSCHRIFT, 1993, 105 (20) : 585 - 588
  • [39] CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy
    Pelissier, Aurelie
    Bonneau, Claire
    Chereau, Elisabeth
    Rouge, Thibault de la Motte
    Fourchotte, Virginie
    Dargi, Emile
    Rouzier, Roman
    GYNECOLOGIC ONCOLOGY, 2014, 135 (03) : 542 - 546
  • [40] PERIPHERAL CA-125 LEVELS IN PATIENTS WITH UTERINE FIBROIDS
    BISCHOF, P
    GALFETTI, MA
    SEYDOUX, J
    VONHOSPENTHAL, JU
    CAMPANA, A
    HUMAN REPRODUCTION, 1992, 7 (01) : 35 - 38
12345